Literature DB >> 20644033

Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.

Pamela A Morganroth1, Mary Elizabeth Kreider, Joyce Okawa, Lynne Taylor, Victoria P Werth.   

Abstract

OBJECTIVES: (1) To determine the prevalence of interstitial lung disease (ILD) and isolated low diffusing capacity for carbon monoxide (DLCO) in a large cohort of outpatients with dermatomyositis. (2) To compare the pulmonary abnormalities of patients with classic dermatomyositis and those with skin-predominant dermatomyositis.
DESIGN: Retrospective cohort study.
SETTING: University hospital outpatient dermatology referral center. Patients Medical records of 91 outpatients with adult-onset dermatomyositis seen between May 26, 2006, and May 25, 2009, were reviewed. MAIN OUTCOME MEASURES: Presence of ILD on thin-slice chest computed tomographic (CT) scans and DLCO.
RESULTS: Of the 71 patients with dermatomyositis who had CT or DLCO data, 16 (23%; 95% confidence interval [CI], 13%-33%) had ILD as defined by CT results [corrected]. All patients with ILD had a reduced DLCO, and the ILD prevalence was not different between patients with skin-predominant dermatomyositis (10 of 35 [29% ]) and those with classic dermatomyositis (6 of 36 [17% ]) (P = .27). Eighteen of 71 patients with dermatomyositis (25%; 95% CI, 15%-36%) (7 of 35 [20%] with skin-predominant dermatomyositis; 11 of 36 [31%] with classic dermatomyositis; P = .41) had a low DLCO in the absence of CT findings showing ILD. The prevalence of malignant disease was higher in patients with classic dermatomyositis than in those with skin-predominant dermatomyositis (P = .02), and no patients with skin-predominant dermatomyositis had internal malignant disease.
CONCLUSIONS: Radiologic ILD and isolated DLCO reductions, which may signify early ILD or pulmonary hypertension, are common in dermatology outpatients with both classic and skin-predominant dermatomyositis. Because DLCO testing is both inexpensive and sensitive for pulmonary disease, it may be appropriate to screen all patients with dermatomyositis with serial DLCO measurements and base further testing on DLCO results.

Entities:  

Mesh:

Year:  2010        PMID: 20644033      PMCID: PMC3010864          DOI: 10.1001/archdermatol.2010.134

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  25 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 2.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 3.  Polymyositis and dermatomyositis (second of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-20       Impact factor: 91.245

4.  Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?

Authors:  Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2002-04       Impact factor: 11.527

5.  Pulmonary hypertension in polymyositis-dermatomyositis: clinical and hemodynamic characteristics and response to vasoactive therapy.

Authors:  O A Minai
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

6.  Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment.

Authors:  Armin Schnabel; Michael Reuter; Jürgen Biederer; Christiane Richter; Wolfgang L Gross
Journal:  Semin Arthritis Rheum       Date:  2003-04       Impact factor: 5.532

7.  Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis.

Authors:  Tomoyuki Fujisawa; Takafumi Suda; Yutaro Nakamura; Noriyuki Enomoto; Kyotaro Ide; Mikio Toyoshima; Hiroshi Uchiyama; Ryoji Tamura; Masaaki Ida; Takeshi Yagi; Kazumasa Yasuda; Hitoshi Genma; Hiroshi Hayakawa; Kingo Chida; Hirotoshi Nakamura
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

8.  Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis.

Authors:  M Fathi; M Dastmalchi; E Rasmussen; I E Lundberg; G Tornling
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

9.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois
Journal:  Arthritis Rheum       Date:  2002-12-15

10.  Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis.

Authors:  V Cottin; F Thivolet-Béjui; M Reynaud-Gaubert; J Cadranel; P Delaval; P J Ternamian; J F Cordier
Journal:  Eur Respir J       Date:  2003-08       Impact factor: 16.671

View more
  15 in total

Review 1.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

2.  Pulmonary hypertension in polymyositis.

Authors:  Han Wang; Tao Liu; Ying-ying Cai; Lian Luo; Meng Wang; Mengmeng Yang; Lin Cai
Journal:  Clin Rheumatol       Date:  2015-10-14       Impact factor: 2.980

3.  Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients.

Authors:  Yuechi Sun; Yuan Liu; Bing Yan; Guixiu Shi
Journal:  Rheumatol Int       Date:  2012-11-10       Impact factor: 2.631

Review 4.  Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis.

Authors:  Patrick D W Kiely; Felix Chua
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

Review 5.  Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

Authors:  Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

6.  The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.

Authors:  David Fiorentino; Lorinda Chung; Jeff Zwerner; Antony Rosen; Livia Casciola-Rosen
Journal:  J Am Acad Dermatol       Date:  2011-04-29       Impact factor: 11.527

7.  Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Shinji Sato; Masataka Kuwana; Rohit Aggarwal
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-05       Impact factor: 4.794

8.  Amyopathic dermatomyositis complicated by pneumomediastinum.

Authors:  Randy Tang; Christian R Millett; Justin J Green
Journal:  J Clin Aesthet Dermatol       Date:  2013-03

9.  Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis.

Authors:  C C Ang; C O Anyanwu; E Robinson; J Okawa; R Feng; M Fujimoto; Y Hamaguchi; V P Werth
Journal:  Br J Dermatol       Date:  2016-11-11       Impact factor: 9.302

10.  Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis.

Authors:  M D George; R Shah; M Kreider; W T Miller; P A Merkel; V P Werth
Journal:  Br J Dermatol       Date:  2016-12-07       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.